Purkiss Capital Advisors LLC Has $808,000 Position in Eli Lilly and Company $LLY

Purkiss Capital Advisors LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 80.3% in the second quarter, Holdings Channel reports. The institutional investor owned 1,037 shares of the company’s stock after buying an additional 462 shares during the period. Purkiss Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $808,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of LLY. WestEnd Advisors LLC increased its stake in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after buying an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC bought a new position in shares of Eli Lilly and Company in the 1st quarter valued at about $27,000. Citizens National Bank Trust Department increased its position in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after acquiring an additional 27 shares during the last quarter. Blume Capital Management Inc. raised its holdings in Eli Lilly and Company by 46.7% during the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after acquiring an additional 14 shares in the last quarter. Finally, IMG Wealth Management Inc. acquired a new position in Eli Lilly and Company during the second quarter valued at approximately $35,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.0%

LLY stock opened at $825.74 on Tuesday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $935.63. The stock has a market cap of $781.53 billion, a price-to-earnings ratio of 53.97, a price-to-earnings-growth ratio of 1.23 and a beta of 0.47. The company has a fifty day moving average price of $770.54 and a two-hundred day moving average price of $769.08. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the firm earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is 39.22%.

Insider Activity at Eli Lilly and Company

In other news, CEO David A. Ricks acquired 1,632 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director J Erik Fyrwald acquired 1,565 shares of the stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the transaction, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 4,514 shares of company stock valued at $2,894,841. Insiders own 0.14% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on LLY shares. Daiwa Capital Markets lowered Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target on the stock. in a research report on Sunday, August 17th. Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Berenberg Bank reissued a “hold” rating and issued a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Finally, Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $938.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.